Navigation Links
Agenda set for upcoming global conference on stem cell therapy to be held Jan. 20-21, 2011
Date:1/5/2011

WHAT: The agenda for the Sixth International Conference on Cell Therapy for Cardiovascular Disease (IC3D) has been set and is available at http://celltherapy.crf.org/conference/agenda.html. The conference, which will be held January 20-21, 2011, is a one-and-a-half day comprehensive program dedicated to the evolving field of cell-based therapies for the repair and regeneration of cardiac and vascular disease, as well as related diseases such as diabetes and stroke. This year's conference will focus on commercialization aspects of the field, highlighting the status of molecular, cell, and tissue products in addition to delivery systems.

WHY: Now in its 10th year of clinical trials, the application of stem cells in the treatment of cardiovascular diseases has seen many notable successes, as well as identified challenges that await the next round of clinical studies. Leaders in the field will convene to present their work, experiences, observations, and opinions on the benefits and unmet challenges of cell-based therapies.

Sessions will focus on:

  • Autologous cell products
  • Allogenic cells, hybrid preparations, and specialty products
  • Molecular interventions: Macro and micro agents
  • Delivery methods and imaging
  • Selection of biologics and methodologies in the development of the next generation of clinical trials

WHO: Warren Sherman, MD, Course Director, is Director of Cardiac Cell-Based Endovascular Therapies at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital and Columbia University Medical Center. Dr. Sherman is a renowned clinical investigator in the field of myocardial regeneration who pioneered a technique for injecting stem cells into the heart. In Rotterdam in May 2001, he performed the first catheter-based injection of stem cells into the heart of a patient with congestive heart failure due t
'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Bersin & Associates Unveils Agenda for Research Conference, IMPACT 2010: The Business of Talent(R)
2. Scientific community to set research agenda for infection prevention and control for next decade
3. National Democratic Strategist Bob Weiner Discusses Healthcare, Political Aftermath, Obama Agenda in Radio Interview
4. Report proposes new research agenda on pregnancy intentions of HIV-positive women
5. Transformation at top of agenda for CPMRCs annual conference in Jan. 2011
6. Republicans Give Top Award to Betsy McCaughey, Healthcare Patriot, & Rev Up for Upcoming Elections
7. SOKO Fitness & Spa Group to Present at Upcoming Investor Conferences
8. Good Vibrations Announces Upcoming Donation Partner: Clitoraid
9. Marin Cosmetic Surgery Center "The Center of Excellence" Celebrating It's Upcoming Tenth Year Anniversary With Miguel A. Delgado, Jr., M.D.
10. Upcoming Simulcast to Teach Women How to Lose Weight and Naturally Balance Hormones with Polycystic Ovarian Syndrome
11. KidsPlay Unplugged, LLC Launches Website; Announces Production of Upcoming DVD's Encouraging Children to Engage in Free Spirited and Imaginary Play
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... In a recent episode of SCI ... Change Athlete Development Services and Consultancy talks with ... athlete development and player engagement during and after their ... athletes face and how off-field activities are a critical ... involved in athlete development issues while in graduate school ...
(Date:2/28/2015)... Oregon (PRWEB) February 28, 2015 The ... Oregon, is offering a new special. Throughout all ... relines. , This service can ... sleep problems and pain. Patients may notice certain symptoms ... need relining. These symptoms include: , 1.    Pain, clicking, ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Indosoft ... software suite for Asterisk, are pleased to announce the ... successful 5.7 and 5.8 versions of Q-Suite, this new ... as a number of new features to the leading ... 2015. , Q-Suite 5.9 will add features to enhance ...
(Date:2/28/2015)... February 28, 2015 Pioneer Millworks reclaimed ... Japan Architecture & Construction Materials Show, an annual, premier ... than 1,000 suppliers and top manufacturers of the latest ... wood products sourced and manufactured by Pioneer Millworks ... popularity in Japan at restaurants, hotels, retailers, and corporate ...
(Date:2/28/2015)... New York, NY (PRWEB) February 28, 2015 ... to discuss federal testosterone lawsuits that have been filed ... scheduled for the second week in March, the Firm ... the Court’s website, parties involved in the federal litigation ... to address matters related to prescription therapy treatments designed ...
Breaking Medicine News(10 mins):Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4
... the disease, , , WEDNESDAY, April 15 (HealthDay News) ... the tracking of changes in cancer cells, according ... Medicine. , The technology uses specially designed dye-containing ... or on a single cell. , Current single-flow ...
... RequirementsTAMPA, Fla., April 15 Sage Software Healthcare, ... today announced that The Certification Commission for Healthcare ... Intergy EHR, as a CCHIT Certified(R) ... certified for Child Health and Cardiovascular Medicine, and ...
... Emory University, developed a test in nonhuman primates that ... cognitive impairment (MCI) in humans. The researchers hope the ... of Alzheimer,s disease. The test, which is featured in ... of Alzheimer,s Disease and Other Dementias , is helping ...
... Dinotefuran and Pyriproxyfen Combination Delivers Safe and Effective Control ... April 15 Summit VetPharm announces the introduction of ... flea control product containing dinotefuran and pyriproxyfen in combination ... that protects your dog from all stages of fleas ...
... Voice-Assisted Care and Pathway Health Services Bring Better ... Facilities in Long-Term CarePITTSBURGH, April 15 Vocollect ... a nationally recognized consulting and management company for ... home care markets, announce an agreement whereby Pathway ...
... April 15 ... landmark in the employee phase of the "Our House is ... and Kemmons Wilson Family Center for Good Grief as they ... began in November of 2008, with 60 employee volunteers across ...
Cached Medicine News:Health News:Sage Intergy EHR Receives 08 CCHIT Certification 2Health News:Sage Intergy EHR Receives 08 CCHIT Certification 3Health News:Sage Intergy EHR Receives 08 CCHIT Certification 4Health News:Sage Intergy EHR Receives 08 CCHIT Certification 5Health News:Yerkes researchers use eye tracking to detect mild dementia in humans 2Health News:Summit VetPharm Offers New Flea Topical Vectra for Dogs & Puppies(TM) For Long-Lasting Protection 2Health News:Summit VetPharm Offers New Flea Topical Vectra for Dogs & Puppies(TM) For Long-Lasting Protection 3Health News:Summit VetPharm Offers New Flea Topical Vectra for Dogs & Puppies(TM) For Long-Lasting Protection 4Health News:Pathway Health Services and Vocollect Healthcare Systems Announce Strategic Partnership 2Health News:Baptist Colleagues Raise $1 Million for Baptist Trinity Hospice House and Kemmons Wilson Family Center for Good Grief 2
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... findings from a pre-clinical study published in the ... ( www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ibrutinib ... antibody (a checkpoint inhibitor), suppression of tumor growth ... achieved when treating certain hematologic cancers and solid ...
(Date:2/27/2015)... Feb. 27, 2015 Securities lawyers at ... Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP ) in ... Concerned SLXP investors are encouraged to contact attorney Hamilton ... The investigation focuses upon the shareholder value of the ... would receive only $158.00 per share in cash. At ...
(Date:2/27/2015)... , Feb. 27, 2015  Boston Scientific Corporation ... in the Barclays 2015 Annual Healthcare Conference on March ... Dan Brennan , executive vice president and ... president, Investor Relations, will participate in a 25-minute question ... analyst at approximately 1:05 p.m. ET. Following a 5-minute ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2
... When treating children for acute osteomyelitis--a bacterial ... to oral antibiotics is just as effective as continuing ... the oral drugs are more convenient for children and ... increased risk of complications from using central catheters, such ...
... Recombinant Factor IX (rFIX) Product for the Treatment of ... Inc., today announced the initiation of a Phase 1 ... IX (rFIX) product for control and prevention of hemorrhagic ... estimated that the market for therapies to treat this ...
Cached Medicine Technology:Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection 2Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection 3Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B 2
2 mm wide curved tip. Round handle....
9 mm blade....
3 mm disposable bevel blades. Malleable shafts. Blades packaged 6 per package....
Straight 6 mm Lance blade. Can be placed in closed handle for protection. Angular handle. Length of sheath handle 105 mm, 4.2 inches....
Medicine Products: